Teleflex Inc (TFX) Stock Analysis and Metrics

Teleflex

NYSE: TFX

$131.93 ▲ +0.77 (+0.59%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap5.85 Bn

P/E-5.80

P/S2.75

Div. Yield0.01

ROIC (Qtr)0.00

Total Debt (Qtr)2.62 Bn

Revenue Growth (1y) (Qtr)32.35

Add ratio to table…

About

Teleflex Incorporated is a global provider of medical technology products that enhance clinical benefits improve patient and provider safety and reduce total procedural costs. The company designs develops manufactures and supplies single use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Teleflex markets and sells its products worldwide through a combination of its direct sales force and distributors.

Teleflex generates revenue primarily from the sale of its medical technology products to hospitals and healthcare providers. The company's product portfolio includes vascular and emergency medicine devices interventional devices and surgical devices. Sales are made directly to end users and through independent distributor networks across the globe.

The company operates through the following segments:.

• The Vascular and Emergency Medicine segment includes products such as Arrow branded catheters catheter navigation and tip positioning systems intraosseous access systems and hemostatic products like the QuikClot brand which support critical care therapies and reduce vascular related complications.

• The Interventional segment offers coronary catheters structural heart support devices peripheral intervention platforms and related products such as the MANTA Vascular Closure device and Arrow OnControl powered bone biopsy system which facilitate diagnosis and treatment of coronary and peripheral vascular disease.

• The Surgical segment comprises single use and reusable devices for surgical procedures including metal and polymer ligating clips fascial closure systems percutaneous surgical systems powered bariatric staplers and instruments used in ear nose and throat and cardio vascular and thoracic procedures under brands such as Weck MiniLap Pleur Evac Deknatel KMedic Pilling and Titan SGS.

Teleflex operates in a highly competitive medical device industry where it faces rivals ranging from small startups to large established corporations with greater financial resources. The company maintains its position by focusing on clinical superiority innovative features product reliability performance customer support and cost effectiveness. Its research and development capabilities commitment to engineering excellence and low cost manufacturing enable it to introduce cost effective innovative products that improve safety efficacy and quality of healthcare.

Teleflex serves hospitals and healthcare providers around the world. Its customers include acute care hospitals ambulatory surgical centers clinics and other health care facilities that purchase its single use medical devices for diagnostic and therapeutic procedures. The company also works with distributors that help reach these end users in various geographic markets.

Investment Thesis

▲ Bull case

Teleflex is executing a portfolio transformation that will leave a pure play focused on vascular access interventional and surgical markets which are poised for durable mid single digit revenue growth year over year and the company expects operating leverage to drive margin expansion as the business scales. The removal of lower growth non core assets through the pending divestitures will reduce the drag on overall profitability and allow management to concentrate resources on higher margin franchises. Once the transition service and manufacturing service agreements are in place the estimated ninety million dollar stranded cost base will be offset resulting in an underlying steady state adjusted operating margin of approximately twenty three% which is four hundred basis points above the current guidance burdened margin of nineteen%. This margin upside combined with a reduced share count from the planned one billion dollar share repurchase and eight hundred million dollar debt paydown could push adjusted earnings per share well beyond the six dollar twenty five to six dollar fifty five range for 2026 and create a meaningful rerating of the stock.
The company has committed to use the net proceeds from the strategic divestitures estimated at approximately one point eight billion dollars after tax to fund a share repurchase authorization of up to one billion dollars and to repay eight hundred million dollars of debt which will materially lower interest expense and increase earnings power. By initiating opportunistic open market repurchases in the second quarter ahead of the divestiture close Teleflex is signalling confidence in its intrinsic value and begins to accrete earnings per share immediately through a reduced share count. The debt paydown will cut annual interest expense which currently runs around one hundred five million dollars for the full year 2026 and will free cash flow for further reinvestment or additional returns to shareholders. These capital actions combined with the expected margin improvement create a clear path to double digit adjusted earnings per share growth in the years following the divestitures and provide a tangible downside protection for the stock.
The appointment of Jason Weidman as President and Chief Executive Officer effective June eighth brings a proven growth leader with deep experience in complex medical technology organizations and a track record of scaling businesses globally which should accelerate the execution of Teleflex is growth strategy. The newly formed Growth and Operating Committee of the Board will provide focused oversight on strategic initiatives and ensure that capital allocation aligns with the highest returning opportunities particularly in the interventional segment where the company is investing heavily in research and development. Management has highlighted that the interventional business is expected to show accelerated growth in the second half of the year as the sales force integration completes and cross selling opportunities in the cath lab begin to materialize. This leadership change and committee structure reduce execution risk and increase the likelihood that Teleflex will achieve or exceed its long term financial objectives.
Teleflex continues to advance its Freesolve drug eluting resorbable magnesium scaffold technology with the BIOMAG II European pivotal trial enrolling patients ahead of schedule positioning the company for a late two thousand twenty seven data readout and the planned initiation of a BIOMAG III US pivotal trial in two thousand twenty six which could unlock a new growth avenue in interventional cardiology. The technology addresses the industry trend toward leaving nothing behind after vascular procedures offering a differentiated product that could command premium pricing and drive market share gains in a high growth niche. Successful trial outcomes would likely lead to regulatory approvals in major markets and create a meaningful revenue stream that is not yet reflected in current consensus estimates. The combination of near term margin expansion from the transformation and a long term pipeline catalyst provides a balanced bullish case that the market may be underestimating.
Teleflex continues to generate solid cash flow from operations with the first quarter delivering forty six million six hundred sixty two thousand dollars of operating cash which provides a reliable internal source to fund working capital needs and support strategic initiatives without over reliance on external financing. The company balance sheet shows cash and cash equivalents of three hundred twenty nine million five hundred fifty thousand dollars at the end of the first quarter giving it flexibility to weather any short term volatility while it pursues its divestiture linked capital return plan. Strong cash generation also allows the firm to sustain its research and development investment at approximately eight% of sales which is critical for maintaining a pipeline of differentiated products in high growth areas such as interventional and surgical. This internal financial strength reduces the risk that the company will need to dilute shareholders or take on additional debt to pursue its growth agenda.

Teleflex is executing a portfolio transformation that will leave a pure play focused on vascular access interventional and surgical markets which are poised for durable mid single digit revenue growth year over year and the company expects operating leverage to drive margin expansion as the business scales. The removal of lower growth non core assets through the pending divestitures will reduce the drag on overall profitability and allow management to concentrate resources on higher margin franchises. Once the transition service and manufacturing service agreements are in place the estimated ninety million dollar stranded cost base will be offset resulting in an underlying steady state adjusted operating margin of approximately twenty three% which is four hundred basis points above the current guidance burdened margin of nineteen%. This margin upside combined with a reduced share count from the planned one billion dollar share repurchase and eight hundred million dollar debt paydown could push adjusted earnings per share well beyond the six dollar twenty five to six dollar fifty five range for 2026 and create a meaningful rerating of the stock.
The company has committed to use the net proceeds from the strategic divestitures estimated at approximately one point eight billion dollars after tax to fund a share repurchase authorization of up to one billion dollars and to repay eight hundred million dollars of debt which will materially lower interest expense and increase earnings power. By initiating opportunistic open market repurchases in the second quarter ahead of the divestiture close Teleflex is signalling confidence in its intrinsic value and begins to accrete earnings per share immediately through a reduced share count. The debt paydown will cut annual interest expense which currently runs around one hundred five million dollars for the full year 2026 and will free cash flow for further reinvestment or additional returns to shareholders. These capital actions combined with the expected margin improvement create a clear path to double digit adjusted earnings per share growth in the years following the divestitures and provide a tangible downside protection for the stock.
The appointment of Jason Weidman as President and Chief Executive Officer effective June eighth brings a proven growth leader with deep experience in complex medical technology organizations and a track record of scaling businesses globally which should accelerate the execution of Teleflex is growth strategy. The newly formed Growth and Operating Committee of the Board will provide focused oversight on strategic initiatives and ensure that capital allocation aligns with the highest returning opportunities particularly in the interventional segment where the company is investing heavily in research and development. Management has highlighted that the interventional business is expected to show accelerated growth in the second half of the year as the sales force integration completes and cross selling opportunities in the cath lab begin to materialize. This leadership change and committee structure reduce execution risk and increase the likelihood that Teleflex will achieve or exceed its long term financial objectives.
Teleflex continues to advance its Freesolve drug eluting resorbable magnesium scaffold technology with the BIOMAG II European pivotal trial enrolling patients ahead of schedule positioning the company for a late two thousand twenty seven data readout and the planned initiation of a BIOMAG III US pivotal trial in two thousand twenty six which could unlock a new growth avenue in interventional cardiology. The technology addresses the industry trend toward leaving nothing behind after vascular procedures offering a differentiated product that could command premium pricing and drive market share gains in a high growth niche. Successful trial outcomes would likely lead to regulatory approvals in major markets and create a meaningful revenue stream that is not yet reflected in current consensus estimates. The combination of near term margin expansion from the transformation and a long term pipeline catalyst provides a balanced bullish case that the market may be underestimating.
Teleflex continues to generate solid cash flow from operations with the first quarter delivering forty six million six hundred sixty two thousand dollars of operating cash which provides a reliable internal source to fund working capital needs and support strategic initiatives without over reliance on external financing. The company balance sheet shows cash and cash equivalents of three hundred twenty nine million five hundred fifty thousand dollars at the end of the first quarter giving it flexibility to weather any short term volatility while it pursues its divestiture linked capital return plan. Strong cash generation also allows the firm to sustain its research and development investment at approximately eight% of sales which is critical for maintaining a pipeline of differentiated products in high growth areas such as interventional and surgical. This internal financial strength reduces the risk that the company will need to dilute shareholders or take on additional debt to pursue its growth agenda.

▼ Bear case

The integration of the Vascular Intervention business acquired from BIOTRONIK is causing disruption in the interventional sales force due to territory realignment and restructuring activities which management acknowledges could weigh on growth in the first half of the year and may persist longer than expected if synergies are delayed. The recent third party supplier recall affecting certain vascular and interventional kits has required a remediation program that could elevate back orders at the end of the second quarter and potentially shift revenue timing into later periods. These operational hiccups increase execution risk and could cause the company to miss its internal growth targets especially in the interventional segment where the company is counting on accelerated second half performance. If the integration takes longer to smooth out the company may need to incur additional costs to restore sales effectiveness which would pressure margins and offset the anticipated benefits of the divestitures.
The company ability to execute its planned one billion dollar share repurchase and eight hundred million dollar debt reduction is contingent on the timely closure of the strategic divestitures which remain subject to antitrust review and have already drawn a second request for information from the U S Federal Trade Commission. Any delay in closing the transactions would postpone the availability of proceeds forcing Teleflex to either slow the repurchase pace or rely on existing cash generation which could limit the immediate accretive effect on earnings per share. Furthermore the company has disclosed that it does not include the anticipated tax benefits from the transition service and manufacturing service agreements in its 2026 operating margin guidance meaning that any shortfall in those fee revenues would keep the burdened margin closer to the current nineteen% level rather than the higher steady state estimate. This dependency on external approvals introduces uncertainty to the capital return plan and could diminish the expected upside to shareholder value.
Teleflex has acknowledged that tariffs are a notable headwind with approximately thirty three million dollars of tariff expense embedded in the full year 2026 guidance and while the company notes that potential refunds could provide upside the timing and magnitude of such recoveries remain uncertain and could be offset by other cost pressures. Logistics and distribution costs have begun to rise as geopolitical tensions persist and the company reliance on global supply chains leaves it vulnerable to freight inflation and potential disruptions that could erode gross margin. The adjusted gross margin for the first quarter declined four hundred seventy basis points year over year driven in part by tariffs higher logistics costs and the lower margin profile of the newly acquired Vascular Intervention business. If these cost pressures prove more durable than anticipated the company may struggle to achieve the targeted adjusted operating margin of around nineteen% for 2026 let alone the higher steady state levels.
The Freesolve drug eluting resorbable magnesium scaffold program while promising remains several years away from potential commercialization with the European pivotal trial not expected to read out until late two thousand twenty seven and a US pivotal trial possibly not delivering data until around two thousand thirty which means near term revenue contribution will be minimal. The company is allocating approximately eight% of sales to research and development which could pressure short term profitability if the pipeline fails to produce viable products and the competitive landscape in interventional cardiology remains intense with multiple large players pursuing similar bioresorbable technologies. Relying on a long dated innovation to drive future growth exposes Teleflex to the risk that market expectations for margin expansion and earnings acceleration may be realized more slowly than anticipated. Furthermore the company current revenue growth guidance of four point five to five point five% pro forma adjusted constant currency reflects a modest outlook that may already be priced in leaving limited upside if the transformation does not exceed expectations.
Teleflex carries a substantial goodwill and intangible asset base resulting from past acquisitions which translates into significant annual amortization expense that weighs on earnings and limits the ability to showcase underlying operational profitability. The adjusted diluted earnings per share reconciliation shows that intangible amortization expense net of tax contributes approximately two dollars and seventeen cents per share to the 2026 adjusted EPS figure meaning that a large portion of the reported profitability is driven by non cash charges. If the company were to face impairment triggers due to overestimation of synergies or slower than expected integration the resulting goodwill write down would further depress earnings and could lead to a negative revision of analyst models. This reliance on acquisition related accounting items introduces a degree of opacity to the true earnings power of the core business.

The integration of the Vascular Intervention business acquired from BIOTRONIK is causing disruption in the interventional sales force due to territory realignment and restructuring activities which management acknowledges could weigh on growth in the first half of the year and may persist longer than expected if synergies are delayed. The recent third party supplier recall affecting certain vascular and interventional kits has required a remediation program that could elevate back orders at the end of the second quarter and potentially shift revenue timing into later periods. These operational hiccups increase execution risk and could cause the company to miss its internal growth targets especially in the interventional segment where the company is counting on accelerated second half performance. If the integration takes longer to smooth out the company may need to incur additional costs to restore sales effectiveness which would pressure margins and offset the anticipated benefits of the divestitures.
The company ability to execute its planned one billion dollar share repurchase and eight hundred million dollar debt reduction is contingent on the timely closure of the strategic divestitures which remain subject to antitrust review and have already drawn a second request for information from the U S Federal Trade Commission. Any delay in closing the transactions would postpone the availability of proceeds forcing Teleflex to either slow the repurchase pace or rely on existing cash generation which could limit the immediate accretive effect on earnings per share. Furthermore the company has disclosed that it does not include the anticipated tax benefits from the transition service and manufacturing service agreements in its 2026 operating margin guidance meaning that any shortfall in those fee revenues would keep the burdened margin closer to the current nineteen% level rather than the higher steady state estimate. This dependency on external approvals introduces uncertainty to the capital return plan and could diminish the expected upside to shareholder value.
Teleflex has acknowledged that tariffs are a notable headwind with approximately thirty three million dollars of tariff expense embedded in the full year 2026 guidance and while the company notes that potential refunds could provide upside the timing and magnitude of such recoveries remain uncertain and could be offset by other cost pressures. Logistics and distribution costs have begun to rise as geopolitical tensions persist and the company reliance on global supply chains leaves it vulnerable to freight inflation and potential disruptions that could erode gross margin. The adjusted gross margin for the first quarter declined four hundred seventy basis points year over year driven in part by tariffs higher logistics costs and the lower margin profile of the newly acquired Vascular Intervention business. If these cost pressures prove more durable than anticipated the company may struggle to achieve the targeted adjusted operating margin of around nineteen% for 2026 let alone the higher steady state levels.
The Freesolve drug eluting resorbable magnesium scaffold program while promising remains several years away from potential commercialization with the European pivotal trial not expected to read out until late two thousand twenty seven and a US pivotal trial possibly not delivering data until around two thousand thirty which means near term revenue contribution will be minimal. The company is allocating approximately eight% of sales to research and development which could pressure short term profitability if the pipeline fails to produce viable products and the competitive landscape in interventional cardiology remains intense with multiple large players pursuing similar bioresorbable technologies. Relying on a long dated innovation to drive future growth exposes Teleflex to the risk that market expectations for margin expansion and earnings acceleration may be realized more slowly than anticipated. Furthermore the company current revenue growth guidance of four point five to five point five% pro forma adjusted constant currency reflects a modest outlook that may already be priced in leaving limited upside if the transformation does not exceed expectations.
Teleflex carries a substantial goodwill and intangible asset base resulting from past acquisitions which translates into significant annual amortization expense that weighs on earnings and limits the ability to showcase underlying operational profitability. The adjusted diluted earnings per share reconciliation shows that intangible amortization expense net of tax contributes approximately two dollars and seventeen cents per share to the 2026 adjusted EPS figure meaning that a large portion of the reported profitability is driven by non cash charges. If the company were to face impairment triggers due to overestimation of synergies or slower than expected integration the resulting goodwill write down would further depress earnings and could lead to a negative revision of analyst models. This reliance on acquisition related accounting items introduces a degree of opacity to the true earnings power of the core business.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password